Acadian Asset Management’s Adtran ADTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.85M Buy
147,706
+58,652
+66% +$594K ﹤0.01% 978
2025
Q4
$771K Buy
+89,054
New +$773K ﹤0.01% 1184
2022
Q1
Sell
-46,887
Closed -$1.07M 1622
2021
Q4
$1.07M Sell
46,887
-183,316
-80% -$3.71M ﹤0.01% 814
2021
Q3
$4.31M Sell
230,203
-254,468
-53% -$5.35M 0.02% 487
2021
Q2
$10M Sell
484,671
-116,206
-19% -$2.25M 0.04% 323
2021
Q1
$10M Sell
600,877
-328,387
-35% -$5.53M 0.04% 333
2020
Q4
$13.7M Buy
929,264
+80,907
+10% +$1.03M 0.05% 283
2020
Q3
$8.7M Buy
848,357
+124,388
+17% +$1.41M 0.04% 336
2020
Q2
$7.91M Buy
723,969
+34,303
+5% +$354K 0.03% 376
2020
Q1
$5.29M Buy
689,666
+227,283
+49% +$1.94M 0.03% 386
2019
Q4
$4.58M Buy
462,383
+39,042
+9% +$372K 0.02% 453
2019
Q3
$4.8M Buy
423,341
+303,057
+252% +$3.6M 0.02% 474
2019
Q2
$1.84M Buy
+120,284
New +$1.92M 0.01% 648

Other funds holding ADTN

Acadian Asset Management's ADTN Position: Q1 2026 in Review

Acadian Asset Management increased its Adtran (ADTN) stake by 66% in Q1 2026, buying an estimated $594K and bringing the position to 147,706 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Acadian Asset Management first reported a position in ADTN in Q2 2019 and has held it in 13 quarters since. The position peaked at $13.7M in Q4 2020. 227 funds tracked by Wall St. Rank hold ADTN as of Q1 2026.

  • Acadian Asset Management held 147,706 shares of Adtran worth $1.85M as of Q1 2026.
  • Acadian Asset Management bought 58,652 Adtran shares in Q1 2026, an estimated $594K.
  • Adtran made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #978 holding.
  • Acadian Asset Management first reported a position in Adtran in Q2 2019 and has held it in 13 quarters since.
  • Acadian Asset Management's Adtran position peaked at $13.7M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Adtran as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.